In vivo, in HAM/TSP, the only IFN-β1a trial thus far resulted in amelioration of motor functions with a corresponding decrease in spontaneous lymphoproliferation, tax mRNA as well as HTLV-1-specific CD8+ cells [15]. This evidence concerns the gene CNTN2 and tropical spastic paraparesis.